
Product Manual


CytoSelect™ 24-Well Cell Invasion Assay (Basement Membrane, Colorimetric Format), Trial Size

Catalog Number

CBA-110-T

4 assays

FOR RESEARCH USE ONLY
Not for use in diagnostic procedures



CELL BIOLABS, INC.

Creating Solutions for Life Science Research


Introduction

The ability of malignant tumor cells to invade normal surrounding tissue contributes in large part to the significant morbidity and mortality of cancers. Invasiveness requires several distinct cellular functions including adhesion, motility, detachment, and extracellular matrix proteolysis. Metastatic cells produce many proteolytic enzymes (e.g. lysosomal hydrolysates, collagenases, plasminogen activators) while the expression of certain cell surface protease receptors is also increased.

Cell Biolabs CytoSelect™ Cell Invasion Assay Kit utilizes basement membrane-coated inserts to assay the invasive properties of tumor cells. This Trial Size kit contains sufficient reagents for the evaluation of 4 samples.

Assay Principle

The CytoSelect™ Cell Invasion Assay Kit contains polycarbonate membrane inserts (8 µm pore size) in a 24-well plate. The upper surface of the insert membrane is coated with a uniform layer of dried basement membrane matrix solution. This basement membrane layer serves as a barrier to discriminate invasive cells from non-invasive cells. Invasive cells are able to degrade the matrix proteins in the layer, and ultimately pass through the pores of the polycarbonate membrane. Finally, the cells are removed from the top of the membrane and the invaded cells are stained and quantified.



Related Products

1. CBA-100: CytoSelect™ 24-Well Cell Migration Assay (8µm, Colorimetric)
2. CBA-100-C: CytoSelect™ 24-Well Cell Migration and Invasion Assay (8µm, Colorimetric)
3. CBA-110-COL: CytoSelect™ 24-Well Cell Invasion Assay (Collagen I, Colorimetric)
4. CBA-110-LN: CytoSelect™ 24-Well Cell Invasion Assay (Laminin I, Colorimetric)
5. CBA-111: CytoSelect™ 24-Well Cell Invasion Assay (Basement Membrane, Fluorometric)
6. CBA-111-COL: CytoSelect™ 24-Well Cell Invasion Assay (Collagen I, Fluorometric)
7. CBA-111-LN: CytoSelect™ 24-Well Cell Invasion Assay (Laminin I, Fluorometric)
8. CBA-112: CytoSelect™ 96-Well Cell Invasion Assay (Basement Membrane, Fluorometric)
9. CBA-112-COL: CytoSelect™ 96-Well Cell Invasion Assay (Collagen I, Fluorometric)
10. CBA-112-LN: CytoSelect™ 96-Well Cell Invasion Assay (Laminin, Fluorometric)
11. CBA-130: CytoSelect™ 96-Well Cell Transformation Assay (Soft Agar Colony Formation)

Kit Components

1. ECM Invasion Chamber Plate (Part No. 11001-T): One 24-well plate containing 4 ECM-coated cell culture inserts.
2. Cell Stain Solution (Part No. 11002-T): One 4 mL bottle
3. Extraction Solution (Part No. 11003-T): One 4 mL bottle
4. Cotton Swabs: (Part No. 11004) 40 each
5. Forceps: (Part No. 11005) One each

Materials Not Supplied

1. Invasive cell lines
2. Cell culture medium
3. Serum free medium, such as DMEM containing 0.5% BSA, 2 mM CaCl₂ and 2 mM MgCl₂
4. Cell culture incubator (37°C, 5% CO₂ atmosphere)
5. Light microscope
6. 96-well microtiter plate
7. Microtiter plate reader

Storage

Store all components at 4°C.

Assay Protocol

1. Under sterile conditions, allow the invasion chamber plate to warm up at room temperature for 10 minutes.
2. Rehydrate the basement membrane layer of the cell culture inserts by adding 300 μL of warm, serum-free media to the inner compartment. Incubate at room temperature for 1 hour.
3. Prepare a cell suspension containing $0.5\text{-}1.0 \times 10^6$ cells/ml in serum free media. Agents that inhibit or stimulate cell invasion can be added directly to the cell suspension.
Note: Overnight starvation may be performed prior to running the assay
4. Carefully remove the rehydration medium (step 2) from the inserts without disturbing the basement membrane layer.
Note: It will not affect the assay performance if a small amount of rehydration medium is left in the compartment
5. Add 500 μL of media containing 10% fetal bovine serum or desired chemoattractant(s) to the lower well of the invasion plate.
6. Add 300 μL of the cell suspension solution to the inside of each insert.
7. Incubate for 24-48 hours at 37°C in 5% CO_2 atmosphere.
8. Carefully aspirate the media from the inside of the insert. Wet the ends of 2-3 cotton-tipped swabs with water, flatten the ends of the swabs by pressing them against a clean hard surface, and gently swab the interior of the inserts to remove non-invasive cells. Take care not to puncture the polycarbonate membrane. Be sure to remove cells on the inside perimeter of the insert.
9. Transfer the insert to a clean well containing 400 μL of Cell Stain Solution and incubate for 10 minutes at room temperature.
10. Gently wash the stained inserts several times in a beaker of water. Allow the inserts to air dry.
11. (optional) Count invasive cells with a light microscope under high magnification objective, with at least three individual fields per insert.
12. Transfer each insert to an empty well, adding 200 μL of Extraction Solution per well, then incubating 10 minutes on an orbital shaker.
13. Transfer 100 μL from each sample to a 96-well microtiter plate and measure the OD 560nm in a plate reader.

Example of Results

The following figures demonstrate typical invasion results with the CytoSelect™ Cell Invasion Assay Kit. One should use the data below for reference only. This data should not be used to interpret actual results.




Figure 1. Human Fibrosarcoma HT-1080 Cell Invasion. HT-1080 and NIH3T3 (negative control) were seeded at 300,000 cells/well and allowed to invade toward 10% FBS for 24 hrs in the presence or absence of 2 μ M Cytochalasin D. Invasive cells on the bottom of the invasion membrane were stained (top panel picture) and quantified at OD 560nm after extraction (bottom panel figure).

References

1. Erckell, L. J., Schirmacher, V. (1988) *Cancer Res* **48**, 6933-6937.
2. Montgomery, A. M. P., De Clerck, Y. A., Langley, K. E., Reisfeld, R. A., Mueller, B. M. (1993) *Cancer Res* **53**,693-700.
3. Monsky, W. L., Lin, C. Y., Aoyama, A., Kelly, T., Akiyama, S. K., Mueller, S. C., Chen, W. T. (1994) *Cancer Res* **54**,5702-5710.

Recent Product Citations

1. Park, J.S. et al. (2022). Gene Expression Analysis of Aggressive Adult Xp11.2 Translocation Renal Cell Carcinoma at Clinical Stage T1N0M0 to Identify Potential Prognostic and Therapeutic Biomarkers. *Biomedicines*. **10**(2):321. doi: 10.3390/biomedicines10020321.
2. Tai, Y.K. et al. (2022). Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach. *Front Oncol*. **11**:783803. doi: 10.3389/fonc.2021.783803.
3. Zhang, J. et al. (2021). Wnt2 Contributes to the Development of Atherosclerosis. *Front Cardiovasc Med*. **8**:751720. doi: 10.3389/fcvm.2021.751720.

4. Zhang, N. et al. (2021). LncRNA FGD5-AS1 functions as an oncogene to upregulate GTPBP4 expression by sponging miR-873-5p in hepatocellular carcinoma. *Eur J Histochem.* **65**(4). doi: 10.4081/ejh.2021.3300.
5. Martínez-López, A. et al. (2021). Inhibition of RAC1 activity in cancer associated fibroblasts favours breast tumour development through IL-1 β upregulation. *Cancer Lett.* **521**:14-28. doi: 10.1016/j.canlet.2021.08.014.
6. Avşar Abdik, E. (2021). Differentiated pre-adipocytes promote proliferation, migration and epithelial-mesenchymal transition in breast cancer cells of different p53 status. *Mol Biol Rep.* doi: 10.1007/s11033-021-06521-8.
7. Chen, H. et al. (2021). Signaling of MK2 sustains robust AP1 activity for triple negative breast cancer tumorigenesis through direct phosphorylation of JAB1. *NPJ Breast Cancer.* **7**(1):91. doi: 10.1038/s41523-021-00300-1.
8. Huang, J. et al. (2021). Long non-coding RNA 00858 knockdown alleviates bladder cancer via regulation of the miR-3064-5p/CTGF axis. *Oncol Rep.* **46**(2):164. doi: 10.3892/or.2021.8115.
9. Albuquerque-González, B. et al. (2021). The FDA-Approved Antiviral Raltegravir Inhibits Fascin1-Dependent Invasion of Colorectal Tumor Cells In Vitro and In Vivo. *Cancers.* **13**(4):861. doi: 10.3390/cancers13040861.
10. Shimizu, K. et al. (2020). ARHGAP29 expression may be a novel prognostic factor of cell proliferation and invasion in prostate cancer. *Oncol Rep.* doi: 10.3892/or.2020.7811.
11. Joseph, C. et al. (2020). The ITIM-Containing Receptor: Leukocyte-Associated Immunoglobulin-Like Receptor-1 (LAIR-1) Modulates Immune Response and Confers Poor Prognosis in Invasive Breast Carcinoma. *Cancers (Basel).* **13**(1):E80. doi: 10.3390/cancers13010080.
12. Bastos, D.C. et al. (2020). Genetic ablation of FASN attenuates the invasive potential of prostate cancer driven by Pten loss. *J Pathol.* doi: 10.1002/path.5587.
13. Lim, W.C. et al. (2020). Polysaccharide isolated from persimmon leaves (*Diospyros kaki* Thunb.) suppresses TGF- β 1-induced epithelial-to-mesenchymal transition in A549 cells. *Int J Biol Macromol.* S0141-8130(20)34246-X. doi: 10.1016/j.ijbiomac.2020.08.155.
14. Daso, R.E. et al. (2020). Self-Assembled Peptide Based Biocomposites for Near Infra-red Light Triggered Drug Release to Tumor Cells. *Biotechnol J.* doi: 10.1002/biot.202000128.
15. Tang, H. et al (2020). MiR-4328 inhibits proliferation, metastasis and induces apoptosis in keloid fibroblasts by targeting BCL2 expression. *Open Life Sci.* **15**(1):638-646. doi: 10.1515/biol-2020-0056.
16. Zhou, R. et al. (2020). ADAM9 Mediates Triple-Negative Breast Cancer Progression via AKT/NF- κ B Pathway. *Front Med (Lausanne).* **7**:214. doi: 10.3389/fmed.2020.00214.
17. Wang, F. et al. (2020). Combination therapy of gefitinib and miR-30a-5p may overcome acquired drug resistance through regulating the PI3K/AKT pathway in non-small cell lung cancer. *Ther Adv Respir Dis.* **14**:1753466620915156. doi: 10.1177/1753466620915156.
18. Chen, C. et al. (2020). The circular RNA 001971/miR-29c-3p axis modulates colorectal cancer growth, metastasis, and angiogenesis through VEGFA. *J Exp Clin Cancer Res.* **39**(1):91. doi: 10.1186/s13046-020-01594-y.
19. Lim, W.C. et al. (2020). Catechol inhibits epidermal growth factor-induced epithelial-to-mesenchymal transition and stem cell-like properties in hepatocellular carcinoma cells. *Sci Rep.* **10**(1):7620. doi: 10.1038/s41598-020-64603-2.
20. Díaz-García, D. et al. (2020). Mesoporous silica nanoparticles functionalized with a dialkoxide diorganotin(IV) compound: In search of more selective systems against cancer cells. *Micropor Mesopor Mat.* doi: 10.1016/j.micromeso.2020.110154.

21. Shimoyama, H. et al. (2020). Partial silencing of fucosyltransferase 8 gene expression inhibits proliferation of Ishikawa cells, a cell line of endometrial cancer. *Biochem Biophys Res.* **22**:100740. doi: 10.1016/j.bbrep.2020.100740.
22. Felsenstein, M. et al. (2020). Generation and characterization of a cell line from an intraductal tubulopapillary neoplasm of the pancreas. *Lab Invest.* doi: 10.1038/s41374-020-0372-0.
23. Montoro-García, S. et al. (2020). Novel anti-invasive properties of a Fascin1 inhibitor on colorectal cancer cells. *J Mol Med (Berl).* doi: 10.1007/s00109-020-01877-z.
24. Olgun, N.S. et al. (2020). Mild Steel and Stainless Steel Welding Fumes Elicit Pro-Inflammatory and Pro-Oxidant Effects in First Trimester Trophoblast Cells. *Am J Reprod Immunol.* doi: 10.1111/aji.13221.
25. Gan, L. et al. (2019). Vitamin C Inhibits Triple-Negative Breast Cancer Metastasis by Affecting the Expression of YAP1 and Synaptopodin 2. *Nutrients.* **11**(12). pii: E2997. doi: 10.3390/nu11122997.
26. Armignacco, R. et al. (2019). The Adipose Stem Cell as a Novel Metabolic Actor in Adrenocortical Carcinoma Progression: Evidence from an In Vitro Tumor Microenvironment Crosstalk Model. *Cancers (Basel).* **11**(12). pii: E1931. doi: 10.3390/cancers11121931.
27. Unterleuthner, D. et al. (2019). Cancer-associated fibroblast-derived WNT2 increases tumor angiogenesis in colon cancer. *Angiogenesis.* doi: 10.1007/s10456-019-09688-8.
28. Ritter, A. et al. (2019). Subcutaneous and Visceral Adipose-Derived Mesenchymal Stem Cells: Commonality and Diversity. *Cells.* **8**(10). pii: E1288. doi: 10.3390/cells8101288.
29. Ritter, A. et al. (2019). Restoration of primary cilia in obese adipose-derived mesenchymal stem cells by inhibiting Aurora A or extracellular signal-regulated kinase. *Stem Cell Res Ther.* **10**(1):255. doi: 10.1186/s13287-019-1373-z.
30. Ling, X. et al. (2019). miR-505 suppresses prostate cancer progression by targeting NRCAM. *Oncology Reports.* doi: 10.3892/or.2019.7231.

Warranty

These products are warranted to perform as described in their labeling and in Cell Biolabs literature when used in accordance with their instructions. THERE ARE NO WARRANTIES THAT EXTEND BEYOND THIS EXPRESSED WARRANTY AND CELL BIOLABS DISCLAIMS ANY IMPLIED WARRANTY OF MERCHANTABILITY OR WARRANTY OF FITNESS FOR PARTICULAR PURPOSE. CELL BIOLABS' sole obligation and purchaser's exclusive remedy for breach of this warranty shall be, at the option of CELL BIOLABS, to repair or replace the products. In no event shall CELL BIOLABS be liable for any proximate, incidental or consequential damages in connection with the products.

Contact Information

Cell Biolabs, Inc.
 7758 Arjons Drive
 San Diego, CA 92126
 Worldwide: +1 858-271-6500
 USA Toll-Free: 1-888-CBL-0505
 E-mail: tech@cellbiolabs.com
www.cellbiolabs.com

©2013-2022: Cell Biolabs, Inc. - All rights reserved. No part of these works may be reproduced in any form without permissions in writing.